Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile

References

• LessaFCMuYBambergWMBurden of Clostridium difficile infection in the United StatesN Engl J Med2015372982583425714160
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention [webpage on the Internet]Clostridium difficile infection (CDI) tracking2017 Available from: https://www.cdc.gov/hai/eip/clostridium-difficile.htmlAccessed August 3, 2018
   Google Scholar
• KociolekLKGerdingDNClinical utility of laboratory detection of Clostridium difficile strain BI/NAP1/027J Clin Microbiol2016541192426511742
   PubMed Web of Science ®Google Scholar
• JohnsonSLouieTJGerdingDNVancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trialsClin Infect Dis201459334535424799326
   PubMed Web of Science ®Google Scholar
• LouieTJMillerMAMullaneKMFidaxomicin versus vancomycin for Clostridium difficile infectionN Engl J Med2011364542243121288078
   PubMed Web of Science ®Google Scholar
• Sheitoyan-PesantCAbou ChakraCNPépinJMarcil-HéguyANaultVValiquetteLClinical and healthcare burden of multiple recurrences of Clostridium difficile infectionClin Infect Dis201662557458026582748
   PubMed Web of Science ®Google Scholar
• DubberkeERSchaeferEReskeKAZilberbergMHollenbeakCSOlsenMAAttributable inpatient costs of recurrent Clostridium difficile infectionsInfect Control Hosp Epidemiol201435111400140725333435
   PubMed Web of Science ®Google Scholar
• ZhangDPrabhuVSMarcellaSWAttributable healthcare resource utilization and costs for patients with primary and recurrent Clostridium difficile infection in the United StatesClin Infect Dis20186691326133229360950
   PubMed Web of Science ®Google Scholar
• WilcoxMHAhirHCoiaJEImpact of recurrent Clostridium difficile infection: hospitalization and patient quality of lifeJ Antimicrob Chemother20177292647265628633368
   PubMed Web of Science ®Google Scholar
• RupnikMWilcoxMHGerdingDNClostridium difficile infection: new developments in epidemiology and pathogenesisNat Rev Microbiol20097752653619528959
   PubMed Web of Science ®Google Scholar
• KyneLWarnyMQamarAKellyCPAsymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin AN Engl J Med2000342639039710666429
   PubMed Web of Science ®Google Scholar
• KyneLWarnyMQamarAKellyCPAssociation between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoeaLancet2001357925118919311213096
   PubMed Web of Science ®Google Scholar
• ZhangZChenXHernandezLDToxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infectionInfect Immun201583140541625385797
   PubMed Web of Science ®Google Scholar
• Federal Drug Administration [webpage on the Internet]FDA briefing document bezlotoxumab injection meeting of the Antimicrobial Drugs Advisory Committee (AMDAC)2016 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiInfectiveDrugsAdvisoryCommittee/UCM505290.pdfAccessed December 10, 2018
   Google Scholar
• Merck Sharp & Dohme Corp [webpage on the Internet]Whitehouse Station, New JerseyZinplava (bezlotoxumab) Prescribing Information; 2016 Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2016/761046s000lbl.pdfAccessed August 9, 2018
   Google Scholar
• YangZRamseyJHamzaTMechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumabInfect Immun201583282283125486992
   PubMed Web of Science ®Google Scholar
• WilcoxMHGerdingDNPoxtonIRBezlotoxumab for prevention of recurrent Clostridium difficile infectionN Engl J Med2017376430531728121498
   PubMed Web of Science ®Google Scholar
• LowyIMolrineDCLeavBATreatment with monoclonal antibodies against Clostridium difficile toxinsN Engl J Med2010362319720520089970
   PubMed Web of Science ®Google Scholar
• ChapinRWLeeTMcCoyCAlonsoCDMahoneyMVBezlotoxumab: could this be the answer for Clostridium difficile recurrence?Ann Pharmacother201751980481028480750
   PubMed Web of Science ®Google Scholar
• BirchTGolanYRizzardiniGEfficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for Clostridium difficile infectionJ Antimicrob Chemother20187392524252829788418
   PubMed Web of Science ®Google Scholar
• PrabhuVSDubberkeERDorrMBCost-effectiveness of bezlotoxumab compared with placebo for the prevention of recurrent Clostridium difficile infectionClin Infect Dis201866335536229106516
   PubMed Web of Science ®Google Scholar
• GerdingDNKellyCPRahavGBezlotoxumab for prevention of recurrent Clostridium difficile infection in patients at increased risk for recurrenceClin Infect Dis201867564965629538686
   PubMed Web of Science ®Google Scholar
• MullaneKWilcoxMGolanYEfficacy of bezlotoxumab (bezlo) in prevention of Clostridium difficile infection recurrence (rCDI) in patients receiving concomitant systemic antibiotics (CAs)Open Forum Infect Dis20163Suppl 12115
   Google Scholar
• NairSYadavDCorpuzMPitchumoniCSClostridium difficile colitis: factors influencing treatment failure and relapse – a prospective evaluationAm J Gastroenterol19989310187318769772047
   PubMed Web of Science ®Google Scholar
• MullaneKMMillerMAWeissKEfficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infectionsClin Infect Dis201153544044721844027
   PubMed Web of Science ®Google Scholar
• BárányPStenvinkelPNordCEBergströmJClostridium difficile infection – a poor prognostic sign in uremic patients?Clin Nephrol199238153571499170
   PubMed Web of Science ®Google Scholar
• MullaneKMCornelyOACrookDWRenal impairment and clinical outcomes of Clostridium difficile infection in two randomized trialsAm J Nephrol201338111123796582
   PubMed Web of Science ®Google Scholar
• GoyalAChatterjeeKYadlapatiSRangaswamiJImpact of end stage kidney disease on costs and outcomes of Clostridium difficile infectionInt J Infect Dis2017628928645569
   PubMed Web of Science ®Google Scholar
• GolanYDupontHLAldomiroFJensenEHHansonMEDorrMBBezlotoxumab (BEZ) for prevention of Clostridium difficile infection (CDI) recurrence (rCDI): outcomes in patients with substantial renal impairment (SRI)Open Forum Infect Dis20174Suppl 1S387
   Google Scholar
• TangYMStoneCDClostridium difficile infection in inflammatory bowel disease: challenges in diagnosis and treatmentClin J Gastroenterol201710211212328210836
   PubMed Web of Science ®Google Scholar
• RodemannJFDubberkeERReskeKASeoDHStoneCDIncidence of Clostridium difficile infection in inflammatory bowel diseaseClin Gastroenterol Hepatol20075333934417368233
   PubMed Web of Science ®Google Scholar
• BossuytPVerhaegenJvan AsscheGRutgeertsPVermeireSIncreasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel diseaseJ Crohns Colitis2009314721172241
   PubMed Web of Science ®Google Scholar
• KellyCPWilcoxMGlerupHAbooNEvesKDorrMBCharacteristics and outcomes in patients with C. difficile infection (CDI) and inflammatory bowel disease: bezlotoxumab versus placeboGastroenterology20171525S340
   Web of Science ®Google Scholar
• WilcoxMKellyCPGlerupHCharacteristics and outcomes in patients with C. difficile infection (CDI) and inflammatory bowel disease: bezlotoxumab vs placeboPaper presented at: ECCMID, 27th European Congress of Clinical Microbiology and Infectious Diseases2017Vienna, Austria
   Google Scholar
• MikamoHAoyamaNSawataMFujimotoGDorrMBYoshinariTThe effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patientsJ Infect Chemother201824212312929097028
   PubMed Web of Science ®Google Scholar
• Bezlotoxumab(MK-6072) Versus placebo in children with Clostridium Difficile infection (CDI) (MK-6072-001)2018 Available from: https://ClinicalTrials.gov/show/NCT3182907Accessed November 27, 2018
   Google Scholar
• ConnellyTMKoltunWASangsterWAn interleukin-4 polymorphism is associated with susceptibility to Clostridium difficile infection in patients with inflammatory bowel disease: results of a retrospective cohort studySurgery2014156476977525239315
   PubMed Web of Science ®Google Scholar
• JiangZDGareyKWPriceMAssociation of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrheaClin Gastroenterol Hepatol20075896496817618838
   PubMed Web of Science ®Google Scholar
• AnanthakrishnanANOxfordECNguyenDDSaukJYajnikVXavierRJGenetic risk factors for Clostridium difficile infection in ulcerative colitisAliment Pharmacol Ther201338552253023848254
   PubMed Web of Science ®Google Scholar
• GareyKWJiangZDGhantojiSTamVHAroraVDupontHLA common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infectionClin Infect Dis201051121406141021058913
   PubMed Web of Science ®Google Scholar
• ShawPShenJDorrMBGenome wide analysis reveals host genetic variants that associate with reduction in Clostridium difficile infection recurrence (rCDI) in patients treated with BezlotoxumabOpen Forum Infect Dis20174Suppl 1S380
   Google Scholar
• GhantojiSSSailKLairsonDRDupontHLGareyKWEconomic healthcare costs of Clostridium difficile infection: a systematic reviewJ Hosp Infect201074430931820153547
   PubMed Web of Science ®Google Scholar
• LucadoJGouldCElixhauserAClostridium difficile infections (CDI) in hospital stays, 2009: statistical brief #124 Healthcare Cost and Utilization Project (HCUP) Statistical BriefsRockville, MDAgency for Healthcare Research and Quality (US)2006
   Google Scholar
• PrabhuVSDubberkeERDorrMBCost-effectiveness of bezlotoxumab compared with placebo for the prevention of recurrent Clostridium difficile infectionClin Infect Dis201866335536229106516
   PubMed Web of Science ®Google Scholar
• LamSWNeunerEAFraserTGDelgadoDChalfinDBCost-effectiveness of three different strategies for the treatment of first recurrent Clostridium difficile infection diagnosed in a community settingInfect Control Hosp Epidemiol201839892493029961435
   PubMed Web of Science ®Google Scholar
• DeshpandeAPasupuletiVThotaPRisk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysisInfect Control Hosp Epidemiol201536445246025626326
   PubMed Web of Science ®Google Scholar
• Abou ChakraCNPepinJSirardSValiquetteLRisk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic reviewPLoS One201496e9840024897375
   PubMed Web of Science ®Google Scholar
• GareyKWSethiSYadavYDupontHLMeta-analysis to assess risk factors for recurrent Clostridium difficile infectionJ Hosp Infect200870429830418951661
   PubMed Web of Science ®Google Scholar
• D’AgostinoRBCollinsSHPencinaKMKeanYGorbachSRisk estimation for recurrent Clostridium difficile infection based on clinical factorsClin Infect Dis201458101386139324599770
   PubMed Web of Science ®Google Scholar
• LexicompBezlotoxumab: Drug InformationWaltham, MAUpToDate2018
   Google Scholar